These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19689280)

  • 41. A need for evidence-based clinical practice guidelines for the use of heparins in the elderly.
    Gouin-Thibault I; Siguret V; Pautas E
    Clin Interv Aging; 2010 Apr; 5():119-21. PubMed ID: 20458349
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
    Lim W; Dentali F; Eikelboom JW; Crowther MA
    Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Treatment and prophylaxis of deep venous thrombosis with low molecular weight heparins (meta-analysis of clinical trials)].
    Valiukiene L; Naudziūnas A; Unikauskas A
    Medicina (Kaunas); 2003; 39(4):352-8. PubMed ID: 12738903
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dosing and monitoring of low-molecular-weight heparins in special populations.
    Duplaga BA; Rivers CW; Nutescu E
    Pharmacotherapy; 2001 Feb; 21(2):218-34. PubMed ID: 11213859
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity.
    Morla S; Deguchi H; Griffin JH
    J Thromb Haemost; 2021 Feb; 19(2):470-477. PubMed ID: 33176060
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
    Pellizzari L; Facchinetti R; Corrà L; Sepe A; Fantin F; Fontana G; Zamboni M; Di Francesco V
    Aging Clin Exp Res; 2018 Jun; 30(6):605-608. PubMed ID: 28808989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
    Samama MM; Bara L; Gerotziafas GT
    Haemostasis; 1994; 24(2):105-17. PubMed ID: 7959358
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency.
    Dolovich LR; Ginsberg JS; Douketis JD; Holbrook AM; Cheah G
    Arch Intern Med; 2000 Jan; 160(2):181-8. PubMed ID: 10647756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
    Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
    Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Search for the heparin antithrombin III-binding site precursor.
    Linhardt RJ; Wang HM; Loganathan D; Bae JH
    J Biol Chem; 1992 Feb; 267(4):2380-7. PubMed ID: 1733939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P; Lindhout T; Hemker HC
    Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging anticoagulants: mechanism of action and future potential.
    Klement P; Rak J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of current and emerging antithrombotics in thrombosis and cancer.
    Mousa SA
    Drugs Today (Barc); 2006 May; 42(5):331-50. PubMed ID: 16801996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.
    Condac E; Strachan H; Gutierrez-Sanchez G; Brainard B; Giese C; Heiss C; Johnson D; Azadi P; Bergmann C; Orlando R; Esmon CT; Harenberg J; Moremen K; Wang L
    Glycobiology; 2012 Sep; 22(9):1183-92. PubMed ID: 22641771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Heparins].
    Marbet GA
    Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heparin surface immobilization through hydrophilic spacers: thrombin and antithrombin III binding kinetics.
    Byun Y; Jacobs HA; Kim SW
    J Biomater Sci Polym Ed; 1994; 6(1):1-13. PubMed ID: 7947469
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-molecular-weight heparin in the treatment of deep venous thrombosis.
    Hauer KE
    West J Med; 1998 Oct; 169(4):240-4. PubMed ID: 9795594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.